Event
RSC-BMCS/SCI Targeted Protein Degradation 5
Katie Headland
Senior Director | Business Development UK
Iolanda Micco
Head | Scientific Officer Integrated Discovery
Targeted protein degradation (TPD) is expanding opportunities to address challenging therapeutic targets. But how can high-throughput assays support the discovery and optimization of effective protein degraders?
At RSC-BMCS/SCI Targeted Protein Degradation 5, Axxam contributed to the scientific discussion on advancing targeted protein degradation through innovative screening strategies and assay technologies.
Iolanda Micco, Scientific Officer Integrated Discovery at Axxam, presented how high-throughput assays can support degrader discovery and optimization.
Flash Talk & Poster Presentation
Targeted Protein Degradation at Scale: High-Throughput Assays Enabling Discovery and Optimization
21 October 2026 | 3:25 PM | F101 – P01
Identifying and optimizing protein degraders requires robust screening approaches capable of assessing compound activity and supporting informed decisions throughout the discovery process.
In her presentation, Iolanda highlighted the role of high-throughput assay technologies in enabling the identification, characterization, and optimization of protein degraders.
The presentation showcased how scalable screening strategies can help address key challenges in targeted protein degradation research.
Advancing Targeted Protein Degradation with High-Throughput Screening
Unlike conventional inhibitors, targeted protein degraders aim to induce the removal of specific proteins through cellular degradation mechanisms.
Developing effective degraders requires suitable assay systems to investigate compound activity, characterize degradation responses, and guide optimization.
At Axxam, our expertise in assay development, high-throughput screening, and hit-to-lead discovery supports the investigation of challenging targets and the progression of promising compounds through early drug discovery.
Meet us at ELRIG Drug Discovery 2026
Axxam was represented at the conference by Katie Headland, Vice President BD & Sales Europe, and Iolanda Micco, Scientific Officer Integrated Discovery.
Interested in discussing targeted protein degradation, screening technologies, or your drug discovery program?